Bilberry

Bilberry anthocyanins inhibit platelet aggregation, demonstrated at 173 mg/day in healthy volunteers. A case report documented rectal bleeding and elevated INR in a patient consuming large amounts of bilberry fruit daily for five years while on warfarin. Bilberry anthocyanins may also modestly inhibit CYP2E1, slightly slowing warfarin clearance. At >100 mg/day anthocyanins, additive anticoagulant risk is clinically significant.

Monitor INR closely if bilberry extracts are co-administered with warfarin or other anticoagulants. Advise patients to avoid high-dose bilberry (>100 mg/day anthocyanins) while on anticoagulant therapy. Discontinue bilberry at least 2 weeks prior to surgery. Flag any unusual bruising or bleeding.

Bilberry anthocyanins inhibit thromboxane A2 synthesis and platelet aggregation via COX-1 inhibition, producing an additive antiplatelet effect when combined with aspirin or clopidogrel. This increases bleeding risk, particularly perioperatively. Demonstrated in vitro and in healthy volunteer studies at 173 mg/day bilberry anthocyanins.

Avoid combination of high-dose bilberry extract (>100 mg/day anthocyanins) with antiplatelet drugs unless under medical supervision. Caution patients taking antiplatelet therapy about the additive bleeding risk. Discontinue bilberry at least 2 weeks before elective surgery.

Bilberry anthocyanins demonstrate antidiabetic properties via antioxidant protection of pancreatic beta cells, inhibition of alpha-glucosidase, and improvement of peripheral insulin sensitivity. In animal models, bilberry extract reduces fasting blood glucose. Additive blood glucose lowering when combined with antidiabetic medications may increase hypoglycemia risk.

Advise diabetic patients using bilberry supplements to monitor blood glucose more frequently. Alert prescribers to the potential for additive hypoglycemic effects, particularly with insulin or sulfonylureas. No dose adjustment routinely required at low-dose supplemental use; caution at higher extract doses.

Bilberry is rich in polyphenols (anthocyanins, tannins, and phenolic acids) that can chelate non-heme iron in the gastrointestinal tract, forming insoluble iron-polyphenol complexes and reducing intestinal iron absorption by 20-40%. This is a physico-chemical interaction in the gut rather than a pharmacokinetic one.

Advise patients to take iron supplements at least 2 hours before or 4 hours after bilberry preparations to minimize the interaction. Monitor haemoglobin and iron indices if long-term co-administration cannot be separated. This interaction is of low clinical significance at typical dietary bilberry consumption.

Bilberry anthocyanins exhibit vasodilatory and endothelium-protective effects via nitric oxide upregulation and reduction of vascular oxidative stress. Concurrent use with antihypertensive medications may produce additive blood pressure-lowering effects. Anthocyanins also improve endothelial function by inhibiting ACE activity in vitro, potentially enhancing the effects of ACE inhibitors.

Monitor blood pressure in patients taking antihypertensive medications alongside bilberry supplements, especially at doses exceeding 300 mg/day standardised extract. Adjust antihypertensive dose if symptomatic hypotension (dizziness, syncope) develops. The interaction is pharmacodynamic; no pharmacokinetic mechanism has been confirmed in humans.

Bilberry leaf extract and anthocyanins demonstrate lipid-lowering properties in diabetic rat models via AMPK activation and inhibition of hepatic lipid synthesis, reducing total cholesterol, LDL, and triglycerides in a manner comparable to ciprofibrate. Concurrent use with statins or fibrates may produce additive lipid-lowering effects. Mild modulation of CYP2E1 and CYP2C11 by bilberry extract (demonstrated in rats) is unlikely to significantly affect statin metabolism at typical human doses.

Monitor lipid panel in patients using bilberry alongside statin therapy. While additive lipid-lowering may be clinically beneficial, monitor for any signs of excessive cholesterol reduction or myopathy. No pharmacokinetic interaction necessitating statin dose adjustment has been established in humans.

Bilberry anthocyanins inhibit platelet aggregation via COX-1 inhibition and reduced thromboxane production, overlapping with the antiplatelet mechanism of NSAIDs. Concurrent use may produce additive effects on platelet function and gastric mucosal integrity. High tannin content in bilberry preparations may also reduce NSAID absorption through bioadhesive coating of the gastric mucosa. A case report in a systematic review noted bilberry fruit consumption associated with gastrointestinal hemorrhage in the context of antiplatelet/anti-inflammatory drug use.

Exercise caution when bilberry supplements are combined with NSAIDs, particularly in patients with peptic ulcer disease or elevated bleeding risk. Monitor for GI bleeding (dark stools, abdominal pain). Space bilberry supplements at least 30-60 minutes away from NSAID doses if gastric tannin absorption interference is a concern.

An in vivo rat study demonstrated that bilberry extract at 0.15-1.5 g/L in drinking water modestly modulated CYP2E1 and CYP2C11 enzymatic activity in liver microsomes after 29-58 days of administration. CYP2E1 is involved in the bioactivation of acetaminophen to its hepatotoxic metabolite N-acetyl-p-benzoquinone imine (NAPQI); mild inhibition could theoretically reduce hepatotoxic risk but may also subtly alter acetaminophen and ethanol elimination kinetics. Clinical significance at standard bilberry doses (100-400 mg extract/day) in humans is considered low.

No dose adjustment of acetaminophen is needed at standard bilberry doses. Use caution with high-dose bilberry extract in patients taking acetaminophen regularly or in those with hepatic impairment. Advise patients not to combine high-dose bilberry with alcohol. Monitor liver enzymes if symptoms of hepatic impairment develop during concurrent use.

Bilberry anthocyanins demonstrate anti-inflammatory activity through inhibition of NF-κB activation and reduction of pro-inflammatory cytokine production (IL-1β, TNF-α, IL-6). These effects theoretically overlap with corticosteroid-mediated anti-inflammatory pathways, potentially producing additive anti-inflammatory benefit. High-tannin bilberry preparations may reduce glucocorticoid bioavailability if taken simultaneously via gut absorption interference.

Space bilberry supplements by at least 1 hour from oral corticosteroid doses to avoid potential absorption interference from tannins. No dose adjustment of corticosteroids is typically required with standard bilberry supplementation. Monitor for any signs of reduced corticosteroid efficacy in patients with conditions requiring precise steroid dosing (e.g., autoimmune disease, adrenal insufficiency).